Olshan Client Pharmacyclics Featured in Numerous Media Reports Announcing First Commercial Drug Approved by FDA

Firm News

The Wall Street Journal, The New York Times and numerous other media outlets reported on the U.S. Food and Drug Administration’s (FDA) approval of Pharmacyclics’ first commercial drug  IMBRUVICA™, as treatment for patients with a rare blood cancer called mantle cell lymphoma. The highly anticipated new cancer drug has attracted considerable attention from doctors, investors and Wall Street analysts. Olshan represented Pharmacyclics in connection with its corporate and securities matters.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager
mmehaj@olshanlaw.com
212.451.2319


Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.